Rubella virus envelope glycoprotein E1 (E1) (E1)

Rubella virus envelope glycoprotein E1 is the primary structural protein on the surface of the Rubella virus and serves as the major target for the host immune response (UniProt: P08563). As a class II viral fusion protein, E1 is responsible for mediating the fusion between the viral envelope and the host cell's endosomal membrane (PubMed: 11831707). This fusion process is triggered by the acidic environment of the endosome, which induces a conformational change in the E1 protein (PubMed: 11831707). E1 exists as a heterodimer with the E2 glycoprotein on the virion surface, a partnership essential for the correct folding and transport of both proteins (PubMed: 16188990). Because E1 contains the principal neutralizing epitopes, it is the critical component for diagnostic serology and the primary antigen for vaccine-induced immunity (PubMed: 25535330). The protein also possesses hemagglutinating activity, allowing the virus to bind to and agglutinate red blood cells (PubMed: 6203618). Successful targeting of E1 through widespread vaccination with live-attenuated strains has been instrumental in preventing Rubella and Congenital Rubella Syndrome (CDC: Rubella). Therapeutic research continues to explore E1 as a target for monoclonal antibodies to treat severe cases or provide passive immunity (PubMed: 25535330).

Other names

E1 glycoproteinRubella E1 proteinSpike protein E1E1 spike protein

Induction of neutralizing antibodies that bind to E1 epitopes, preventing viral attachment to host receptors and inhibiting pH-dependent membrane fusion within the endosome.